Literature DB >> 4273828

The effects of various "nicotine-like" agents in the cat superior cervical ganglion in situ.

W Haefely.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4273828     DOI： 10.1007/bf00500613

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  31 in total

1.  Dual action of nicotine on the sympathetic ganglion of the cat.

Authors:  A LUNDBERG; S THESLEFF
Journal:  Acta Physiol Scand       Date:  1953

2.  Effect of amphetamine on the synaptic transmission of sympathetic ganglia and spinal cord.

Authors:  J V LUCO; R MARTORELL; A REID
Journal:  J Pharmacol Exp Ther       Date:  1949-10       Impact factor: 4.030

3.  Some properties of the presynaptic nerve terminals in a mammalian sympathetic ganglion.

Authors:  Y Dunant
Journal:  J Physiol       Date:  1972-03       Impact factor: 5.182

4.  The effect of 5-hydroxytryptamine, dimethylphenylpiperazinium and acetylcholine on transmission and surface potential in the cat sympathetic ganglion.

Authors:  J Machová; D Boska
Journal:  Eur J Pharmacol       Date:  1969-08       Impact factor: 4.432

5.  Cholinergic synaptic potentials and the underlying ionic mechasims.

Authors:  K Koketsu
Journal:  Fed Proc       Date:  1969 Jan-Feb

6.  A comparison of the ganglionic stimulating and blocking properties of some nicotinic drugs.

Authors:  J Jaramillo; R L Volle
Journal:  Arch Int Pharmacodyn Ther       Date:  1968-07

7.  Dissociation of depolarization and ganglionic blockade induced by nicotine.

Authors:  G L Gebber
Journal:  J Pharmacol Exp Ther       Date:  1968-03       Impact factor: 4.030

8.  Potentials in isolated rat superior cervical ganglia produced by nicotine.

Authors:  D A Brown; C N Scholfield
Journal:  Br J Pharmacol       Date:  1970-11       Impact factor: 8.739

9.  Depolarization of normal and preganglionically denervated superior cervical ganglia by stimulant drugs.

Authors:  D A Brown
Journal:  Br J Pharmacol Chemother       Date:  1966-03

10.  3H-Nicotine in cat superior cervical and nodose ganglia after close-arterial injection in vivo.

Authors:  D A Brown; P C Hoffmann; L J Roth
Journal:  Br J Pharmacol       Date:  1969-03       Impact factor: 8.739
View more
  8 in total

1.  The effects of 5-hydroxytryptamine and some related compounds on the cat superior cervical ganglion in situ.

Authors:  W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

2.  Blockade by lobeline of potassium exchange in skeletal muscle. Relationship to receptor desensitization at the endplate.

Authors:  R L Volle
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

3.  Muscarinic postsynaptic events in the cat superior cervical ganglion in situ.

Authors:  W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

Review 4.  Nicotinic agonists, antagonists, and modulators from natural sources.

Authors:  John W Daly
Journal:  Cell Mol Neurobiol       Date:  2005-06       Impact factor: 5.046

5.  Discriminative stimulus properties of nicotine: further evidence for mediation at a cholinergic receptor.

Authors:  J A Pratt; I P Stolerman; H S Garcha; V Giardini; C Feyerabend
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

6.  Characterization of the receptor mediating the nicotine discriminative stimulus.

Authors:  C Romano; A Goldstein; N P Jewell
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  The effects of l,l-dimethyl-4-phenyl-piperazinium (DMPP) in the cat superior cervical ganglion in situ.

Authors:  W Haefely
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1974       Impact factor: 3.000

Review 8.  From toxins targeting ligand gated ion channels to therapeutic molecules.

Authors:  Adak Nasiripourdori; Valérie Taly; Thomas Grutter; Antoine Taly
Journal:  Toxins (Basel)       Date:  2011-03-21       Impact factor: 4.546
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.